|Bid||82.83 x 100|
|Ask||83.27 x 200|
|Day's Range||82.01 - 83.37|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||9.04|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Dividend & Yield||2.08 (2.53%)|
|1y Target Est||82.67|
Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.
Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.
The biotech has $36.6 billion on the books, but the money might not be sitting in the right account.